Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
G1 Therapeutics, Inc. - Common Stock
(NQ:
GTHX
)
7.150
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about G1 Therapeutics, Inc. - Common Stock
< Previous
1
2
Next >
Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy
June 04, 2023
From
G1 Therapeutics
Via
GlobeNewswire
New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer
May 16, 2023
Real-World Data Show No Association Between Patient Characteristics and Risk of Myelosuppressive Events
From
G1 Therapeutics
Via
GlobeNewswire
New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)
May 10, 2023
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights
May 03, 2023
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
March 01, 2023
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
February 13, 2023
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
January 09, 2023
From
G1 Therapeutics
Via
GlobeNewswire
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
December 07, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)
November 30, 2022
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:LLY),(NASDAQ:NEO),(NYSE:ZYME),(NASDAQ:GTHX) EQNX::TICKER_END
Via
FinancialNewsMedia
G1 Therapeutics Announces Closing of Offering of Common Stock
November 22, 2022
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Announces Pricing of Offering of Common Stock
November 17, 2022
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Announces Proposed Public Offering of Common Stock
November 17, 2022
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Provides Third Quarter 2022 Financial Results and Operational Highlights
November 02, 2022
From
G1 Therapeutics
Via
GlobeNewswire
Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (ADC)
November 02, 2022
- Data Suggest On-Target Effect of Trilaciclib May Reduce Rates of Myelosuppression, Diarrhea, and Potentially Alopecia Associated with Sacituzumab Govitecan-Hziy -
From
G1 Therapeutics
Via
GlobeNewswire
G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (TNBC)
October 10, 2022
From
G1 Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.